tbuckley/cabot-search huggingface dataset:
Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy
Authors: Charlotte L. van Veldhuisen, Anouk E. J. Latenstein, Helga Blauw, Lyan B. Vlaskamp, Michel Klaassen, Daan J. Lips, Bert A. Bonsing, Erwin van der Harst, Martijn W. J. Stommel, Marco J. Bruno, Hjalmar C. van Santvoort, Casper H. J. van Eijck, Susan van Dieren, Olivier R. Busch, Marc G. Besselink, J. Hans DeVries, Sarah E. Siegelaar, Ralph de Vries
Journal: JAMA Surgery (2022)

Glucose control in patients after total pancreatectomy is problematic because of the complete absence of α- and β-cells, leading to impaired quality of life. A novel, bihormonal artificial pancreas (BIHAP), using both insulin and glucagon, may improve glucose control, but studies in this setting are lacking.To assess the efficacy and safety of the BIHAP in patients after total pancreatectomy.This randomized crossover clinical trial compared the fully closed-loop BIHAP with current diabetes care (ie, insulin pump or pen therapy) in 12 adult outpatients after total pancreatectomy. Patients were recruited between August 21 and November 16, 2020. This first-in-patient study began with a feasibility phase in 2 patients. Subsequently, 12 patients were randomly assigned to 7-day treatment with the BIHAP (preceded by a 5-day training period) followed by 7-day treatment with current diabetes care, or the same treatments in reverse order. Statistical analysis was by Wilcoxon signed rank and Mann-Whitney U tests, with significance set at a 2-sided P < .05.The primary outcome was the percentage of time spent in euglycemia (70-180 mg/dL [3.9-10 mmol/L]) as assessed by continuous glucose monitoring.In total, 12 patients (7 men and 3 women; median [IQR] age, 62.5 [43.1-74.0] years) were randomly assigned, of whom 3 did not complete the BIHAP phase and 1 was replaced. The time spent in euglycemia was significantly higher during treatment with the BIHAP (median, 78.30%; IQR, 71.05%-82.61%) than current diabetes care (median, 57.38%; IQR, 52.38%-81.35%; P = .03). In addition, the time spent in hypoglycemia (<70 mg/dL [3.9 mmol/L]) was lower with the BIHAP (median, 0.00% [IQR, 0.00%-0.07%] vs 1.61% [IQR, 0.80%-3.81%]; P = .004). No serious adverse events occurred.Patients using the BIHAP after total pancreatectomy experienced an increased percentage of time in euglycemia and a reduced percentage of time in hypoglycemia compared with current diabetes care, without apparent safety risks. Larger randomized trials, including longer periods of treatment and an assessment of quality of life, should confirm these findings.trialregister.nl Identifier: NL8871.
Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome
Authors: Pamela B. Allen, Subir Goyal, Tim Niyogusaba, Colin O’Leary, Amy Ayers, Erica S. Tarabadkar, Mohammad K. Khan, Mary Jo Lechowicz
Journal: JAMA Dermatology (2022)

Importance Mycosis fungoides and Sézary syndrome (MF/SS) has an increased incidence in Black patients, but clinical characteristics, treatments, and outcomes have been poorly characterized. Objective To assess racial differences in presentation and outcome and identify drivers for racial disparities in MF/SS. Design, Setting, and Participants A retrospective cohort analysis was conducted of 566 patients with MF/SS diagnosed from 1990 to 2020 and seen at the Winship Cancer Institute of Emory University and Grady Memorial Hospital, both in Atlanta, Georgia. Self-reported race and ethnicity were obtained from patient medical records and analyzed as 2 groups: non-Hispanic Black (Black) and all other races and ethnicities, including Asian, Hispanic, White, and unknown/undeclared (non-Black). Main Outcomes and Measures Univariate and multivariable models and Kaplan-Meier assessments were analyzed for overall survival and time to next treatment. The primary outcome was to assess differences in overall survival by racial and ethnic group. The hypotheses were formulated prior to data collection. Results Of the 566 patients with MF/SS identified (mean [SD] age 55 [16.4] years; 270 (47.7%) female), 257 were Black and 309 were non-Black. Black race was associated with increased rates of progression to a higher TNMB stage (39.8% in Black patients vs 29.1% in non-Black patients; P &amp;amp;lt; .001) but not survival. Black patients were younger and had increased female predominance, higher TNMB stage, higher tumor stage, nodal involvement, and higher lactate dehydrogenase level compared with non-Black patients with MF/SS. Hypopigmented MF (HMF) was found in 62 patients, who were mostly Black (n = 59). Hypopigmented MF was significantly associated with survival on univariate and multivariable models, with 10-year survival of 100% in patients with HMF compared with 51.8% in patients without HMF. Black race was only associated with inferior outcomes after excluding patients with HMF who were younger than 60 years (hazard ratio [HR], 1.61; 95% CI, 1.02-2.55; P = .04), but not in patients older than 60 years (HR, 1.20; 95% CI, 0.80-1.81; P = .37). On multivariate analysis, among the cohort without HMF who were younger than 60 years, Black race remained statistically significant when controlling for cancer stage and large-cell transformation (HR, 1.27; 95% CI, 1.08-2.87; P = .43). Conclusions and Relevance In this cohort study, Black patients with MF/SS showed distinct clinical presentations and patterns of progression with heterogeneous outcomes depending on age at presentation and presence of HMF.
Condensing our understanding of endocytosis
Authors: Lauren C. Panzera, Michael B. Hoppa
Journal: Neuron (2022)

In this issue of Neuron, Imoto et al. report that a splice variant of dynamin (Dyn1xA) interacts with syndapin to form a molecular condensate at the edge of the presynaptic active zone. This enables rapid recruitment of proteins to endocytic sites essential for powering ultrafast endocytosis. In this issue of Neuron, Imoto et al. report that a splice variant of dynamin (Dyn1xA) interacts with syndapin to form a molecular condensate at the edge of the presynaptic active zone. This enables rapid recruitment of proteins to endocytic sites essential for powering ultrafast endocytosis. Dynamin is primed at endocytic sites for ultrafast endocytosisImoto et al.NeuronJuly 8, 2022In BriefImoto et al. demonstrate that a splice variant of Dynamin 1, Dyn1xA, mediates vesicle scission during ultrafast endocytosis. For such a rapid event, Dyn1xA molecules are concentrated at endocytic zones through molecular condensation with Syndapin 1. This cache of Dyn1xA accelerates the kinetics of endocytosis by 100-fold. Full-Text PDF Open Access
Bio-distribution and longevity of mesenchymal stromal cell derived membrane particles
Authors: J. Vos, H. Tejeda-Mora, A. Merino, L. Wu, W.W. Woud, J.A.A. Demmers, W.F.J. van IJcken, M.E.J. Reinders, M.J. Hoogduijn
Journal: Journal of Controlled Release (2022)

Vesicle-based medicines hold great promise for therapy development but essential knowledge on the bio-distribution and longevity of vesicles after administration is lacking. We generated vesicles from the membranes of human mesenchymal stromal cells (MSC) and we demonstrated earlier that these so-called membrane particles (MP) mediate immunomodulatory and regenerative responses in target cells. In the present study we examined the bio-distribution and longevity of MP after intravenous administration in mice. While most vesicle tracking methods are based on imaging techniques, which require labeling of vesicles and can only detect dense accumulations of vesicles, we used proteomics analysis to detect the presence of MP-derived proteins in multiple organs and tissues. MP proteins were mainly present in plasma and leukocytes at 1 h after injection, indicating that MP - in contrast to whole MSC - do not accumulate in the lungs upon first passage but remain in circulation. After 24 h, MP proteins were still present in plasma but were most abundant in the liver. RNA sequencing of livers demonstrated that MP impact liver function and in particular induce metabolic pathways. These data provide a clear view of the bio-distribution and longevity of MP, which is likely extrapolatable to other types of vesicles, and demonstrate that MP circulate for up to 24 h and may be a tool for targeting the liver.
Genomic insights into the evolutionary history and diversification of bulb traits in garlic
Authors: Ningyang Li, Xueyu Zhang, Xiudong Sun, Siyuan Zhu, Yi Cheng, Meng Liu, Song Gao, Jiangjiang Zhang, Yanzhou Wang, Xiai Yang, Jianrong Chen, Fu Li, Qiaoyun He, Zheng Zeng, Xiaoge Yuan, Zhiman Zhou, Longchuan Ma, Taotao Wang, Xiang Li, Hanqiang Liu, Yupeng Pan, Mengyan Zhou, Chunsheng Gao, Gang Zhou, Zhenlin Han, Shiqi Liu, Jianguang Su, Zhihui Cheng, Shilin Tian, Touming Liu
Journal: Genome biology (2022)

Garlic is an entirely sterile crop with important value as a vegetable, condiment, and medicine. However, the evolutionary history of garlic remains largely unknown.Here we report a comprehensive map of garlic genomic variation, consisting of amazingly 129.4 million variations. Evolutionary analysis indicates that the garlic population diverged at least 100,000 years ago, and the two groups cultivated in China were domesticated from two independent routes. Consequently, 15.0 and 17.5% of genes underwent an expression change in two cultivated groups, causing a reshaping of their transcriptomic architecture. Furthermore, we find independent domestication leads to few overlaps of deleterious substitutions in these two groups due to separate accumulation and selection-based removal. By analysis of selective sweeps, genome-wide trait associations and associated transcriptomic analysis, we uncover differential selections for the bulb traits in these two garlic groups during their domestication.This study provides valuable resources for garlic genomics-based breeding, and comprehensive insights into the evolutionary history of this clonal-propagated crop.
EP14.05-020 Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)
Authors: S.M. Moore, L.J. Zhan, G. Liu, R. Rittberg, D. Patel, D. Chowdhury, B. Leung, S. Cheng, M. Mckinnon, K. Khan, J. Agulnik, W.Y. Cheung, D. Dawe, A.S. Fung, S. Snow, V. Cohen, M. Yan, B.H. Lok, P. Wheatley-Price, C. Ho
Journal: Journal of Thoracic Oncology (2022)
EP16.03-021 Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
Authors: L.E. Raez, Y. Baca, M. Nagasaka, J. Nieva, H. Mandani, A. Wanderwalde, H. Borghaei, C. Naban, C. Langer, M.A. Socinsky, G. Lopes, H. Khan, A. Wozniak, C. Carracedo, S. Liu
Journal: Journal of Thoracic Oncology (2022)
EP14.01-014 Risk Factors for Brain Metastasis in Patients with Small Cell Lung Cancer: A Systematic Review and Meta-analysis
Authors: H. Zeng, D. Zheng, W. Witlox, A. Levy, A. Traverso, F.-M.S. Kong, R. Houben, D. De Ruysscher, L. Hendriks
Journal: Journal of Thoracic Oncology (2022)
EP10.01-013 Erector Spinae Plane Block for Post-thoracotomy Analgesia; Comparison with Intercostal Block; Preliminary Results
Authors: K.A. Kavak, Ç. Yıldırım Güçlü, Y. Kahya, B.C. Meço, B. Şafak
Journal: Journal of Thoracic Oncology (2022)
EP14.02-002 Cisplatin in Combination with Entinostat exerts Synergistic Antineoplastic Activity in Small Cell Lung Cancer
Authors: A. Schwendenwein, K. Boettiger, I. Kovacs, N. Barany, C. Lang, Z. Megyesfalvi, M. Grusch, C. Kowol, M. Rezeli, K. Hoetzenecker, B. Dome, K. Schelch
Journal: Journal of Thoracic Oncology (2022)
EP11.01-005 Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients
Authors: V. Hofman, S. Heeke, C. Bontoux, L. Chalabreysse, M. Barritault, P.P. Bringuier, T. Fenouil, N. Benzerdjeb, H. Begueret, J.P. Merlio, C. Caumont, N. Piton, J.-C. Sabourin, S. Evrard, C. Syrykh, A. Vigier, P. Brousset, J. Mazières, E. Long-Mira, J. Benzaquen, V. Tanga, V. Lespinet-Fabre, S. Lassalle, C.-H. Marquette, M. Ilié, P. Hofman
Journal: Journal of Thoracic Oncology (2022)
EP08.01-067 Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
Authors: T. Hoang, M.J. Elliot, C. Poletes, M. Makarem, L. Corke, J. Weiss, M.-S. Tsao, P. Bradbury, F.A. Shepherd, G. Liu, N. Leighl, A. Sacher, S.C.M. Lau
Journal: Journal of Thoracic Oncology (2022)
EP14.05-001 Chemoimmunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer and ECOG Performance Status of 2 or 3
Authors: M. Agarwal, A. Liu, B. Langlais, K. Leventakos, N.Y. Yu, D. Almquist, R. Manochakian, V. Ernani
Journal: Journal of Thoracic Oncology (2022)
EP08.01-094 A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
Authors: L. Wu, X. Pu, G. Lin, M. Xiao, J. Lin, Q. Wang, Y. Kong, X. Yan, F. Xu, Y. Xu, J. Li, K. Li, B. Chen, X. Wen, Y. Tan
Journal: Journal of Thoracic Oncology (2022)
EP08.02-075 Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
Authors: J.B. Sørensen, E.M. Urbanska, L.C. Melchior, E. Santoni-Rugiu
Journal: Journal of Thoracic Oncology (2022)
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
Authors: E.G. Pizzutilo, A.G. Agostara, S. Oresti, D. Signorelli, L.G. Giannetta, S. Stabile, C. Lauricella, A. Amatu, M. Brambilla, G. Lo Russo, C. Proto, L. Mazzeo, T. Beninato, M. Siringo, R. Giusti, M. Filetti, C. Genova, G. Barletta, M. Russano, G.R. Di Fazio, E. Tosoni, G. Metro, S. Pilotto, A. Carta, F. Mazzoni, E. Roca, A.J. Gelibter, S. Gori, R. Berardi, G. Cerea, A. Sartore-Bianchi, S. Siena
Journal: Journal of Thoracic Oncology (2022)
EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Authors: J. Li, X. Pu, B. Zhang, J. Zhang, T.S. Mok, K. Nakagawa, R. Rosell, Y. Cheng, X. Zhou, M.R. Migliorino, S. Niho, K.H. Lee, J. Corral, A. Pluzanski, J. Li, R. Linke, F. Pan, Y. Tang, W. Tan, L. Wu
Journal: Journal of Thoracic Oncology (2022)
EP08.02-124 Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC
Authors: P. Begum, H. O'Sullvan, P. D’Arienzo, N. Cunningham, J. Vick, J. Bhosle, M. Davidson, A. Minchom, M. O'Brien, N. Yousaf, W. Cui, S. Popat
Journal: Journal of Thoracic Oncology (2022)
EP08.01-005 A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL
Authors: A. Hata, M. Nishio, H. Akamatsu, Y. Goto, H. Hayashi, S. Miura, A. Gemma, I. Yoshino, T. Misumi, O. Hataji, K. Nakatani, M. Seike, N. Yanagitani, T. Kumagai, S. Hara, S. Iwasawa, S. Nakagawa, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2022)
EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Authors: A. Delmonte, L. Bonanno, L. Landi, K. Andrikou, A. Dal Maso, G. Minuti, M. Papi, G. Metro, I. Attili, F. Piantedosi, S. Pilotto, S. Gori, G. Rossi, S. Buglioni, D. Giannarelli, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2022)
EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
Authors: M. Tamiya, Y. Goto, H. Kenmotsu, T. Kurata, S. Murakami, N. Yanagitani, H. Taniguchi, S. Kuyama, J. Shimizu, T. Yokoyama, N. Shimada, Maeda T., A. Tamiya, A. Uchiyama, K. Imaizumi, T. Takahama, M. Nishio, H. Hayashi, N. Shiraiwa, M. Okura, H. Kikkawa, D. Thomaidou, T. Kato
Journal: Journal of Thoracic Oncology (2022)
EP10.01-005 Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs
Authors: R. Laidsaar-Powell, P. Butow, B. Brown, K. Mander, J. Young, E. Stone, V. Chin, E. Banks, C. Lim, N. Rankin
Journal: Journal of Thoracic Oncology (2022)
EP08.02-091 Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
Authors: Y. Li, Z. Xu, S. Wang, Y. Zhu, D. Ma, Y. Mu, J. Ying, P. Xing, J. Li
Journal: Journal of Thoracic Oncology (2022)
EP08.02-081 Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Authors: J.W. Neal, F.L. Lim, S.P. Aix, S. Viteri, A. Santoro, K. Spencer, B. Fang, P. Khrizman, J. Kim, V. Subbiah, R. Sudhagoni, L. Samaraweera, L. Andrianova, E. Felip
Journal: Journal of Thoracic Oncology (2022)
EP08.02-063 SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Authors: Q. Zhou, J. Li, J. Wang, L. Yang, J. Fang, X. Dong, T. Yi, X. Min, F. Xu, J. Chen, D. Zhong, J. Bai, L. Liu, A. Zeng, J. Tang, H. Wu, X. Luo, J. Yu, W. Su, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2022)
EP16.01-028 Immunomodulatory Effects of Cryoablation Combined With Immune Checkpoint Inhibitors in a Murine Lung Cancer Model
Authors: Y. Yamauchi, Y. Yamamoto, F. Yokote, H. Dejima, Y. Saito, Y. Sakao, M. Kawamura
Journal: Journal of Thoracic Oncology (2022)
EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial
Authors: D.H. Owen, G.A. Durm, L. Wei, C. Pilcher, S. Ferguson, B. Benner, M. Jukich, V. Sukrithan, B. Konda, H. Savardekar, D. Spakowicz, E. Schwarz, R.O. Norman, R. Wesolowski, W.E. Carson, J. Kaufman, A. Alahmadi, R. Memmott, P. Shields, K. He, E.M. Bertino, C.J. Presley, D.P. Carbone, G.A. Otterson
Journal: Journal of Thoracic Oncology (2022)
EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
Authors: N. Jordana, C. Esparré, R. Román, C. Aguado, B. García, M. Vives, E. Marín, S. García-Román, A. Aguilar, N. Reguart, R. Rosell, M.A. Molina-Vila
Journal: Journal of Thoracic Oncology (2022)
EP08.02-133 Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
Authors: R. Morita, A. Hata, T. Ota, T. Sumi, H. Yoshioka, J. Osugi, Y. Fujisaka, M. Mitsui, S. Morita, N. Katakami
Journal: Journal of Thoracic Oncology (2022)
EP08.02-031 NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
Authors: C. Arolt, M. Dugan, R. Wild, V. Richartz, B. Holz, A.H. Scheel, J. Brägelmann, S. Merkelbach-Bruse, J. Wolf, R. Büttner, F. Lafleur, M. Scheffler, L. Catanzariti, A. Hillmer
Journal: Journal of Thoracic Oncology (2022)
EP11.01-004 An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer
Authors: G. Pelizzari, L. Caggiari, M. Battiston, F. Cortiula, G. Targato, S. Buriolla, M. Bortolot, S. Torresan, M. Alberti, A. Michelotti, G. Bortolus, S. Urban, S. Pizzolitto, G. Fasola, A. Follador, G. De Maglio
Journal: Journal of Thoracic Oncology (2022)
EP08.02-035 Clinical Utility of Liquid Biopsy After Progression to First and Second-Generation TKIs in Advanced EGFR Mutant NSCLC Patients
Authors: D. Heredia, L. Lara-Mejía, G. Cruz-Rico, A. Valencia-Velarde, D. Cárdenas-Fernández, L. Bolaño-Guerra, E. Varela-Santoyo, M. Orozco, L. Cabrera-Miranda, M. Ramos-Ramírez, O. Arrieta
Journal: Journal of Thoracic Oncology (2022)
EP16.02-027 Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients
Authors: Y. Bossé, C. Abbosh, M. Abadier, A. Das Gupta, V. Saavedra Armero, N. Gaudreault, M. Orain, F. Lamaze, J. Tom, C. Melton, T. Hung, D. Hodgson, P. Joubert
Journal: Journal of Thoracic Oncology (2022)
EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
Authors: M-j. Ahn, F. De Marinis, L. Bonanno, B.C. Cho, T.-M. Kim, S. Cheng, S. Novello, C. Proto, S.-W. Kim, J.S. Lee, G. Metro, J.C. Yang, W. Xu, R. Hartmaier, A. Telaranta-Keerie, L. Poole, L. Sequist
Journal: Journal of Thoracic Oncology (2022)
EP08.01-043 Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
Authors: J. Alessi, A. Elkrief, B. Ricciuti, A. Cortellini, X. Wang, V.R. Vaz, A. Barrichello, G. Lamberti, C. Fulgenzi, F. Pecci, D.J. Pinato, A.J. Schoenfeld, M.M. Awad
Journal: Journal of Thoracic Oncology (2022)
EP14.02-006 Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer
Authors: K. Boettiger, A. Schwendenwein, C. Lang, Z. Megyesfalvi, K. Hoetzenecker, M. Rezeli, B. Dome, K. Schelch
Journal: Journal of Thoracic Oncology (2022)
EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation
Authors: T. Fujino, K. Suda, T. Koga, A. Hamada, S. Ohara, M. Chiba, M. Shimoji, T. Takemoto, J. Soh, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2022)
EP16.03-004 Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition
Authors: A.I. Tüns, C.S.L. Ho, H.-U. Schildhaus, M. Wiesweg, B.M. Grüner, B. Hegedüs, M. Schuler, A. Schramm, S. Oeck
Journal: Journal of Thoracic Oncology (2022)
EP08.01-017 Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer
Authors: C.-K. Park, H.R. Jun, H.-J. Oh, J.-Y. Lee, H.-J. Cho, Y.-C. Kim, J.E. Lee, S.H. Yoon, C.M. Choi, J.C. Lee, S.Y. Lee, S.Y. Lee, S.-M. Chun, I.-J. Oh
Journal: Journal of Thoracic Oncology (2022)
EP08.02-015 The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center
Authors: A.P. Maity, M.P. Gangrieddy, K.P. Degen, F. Al-Saleem, J.P. Bramson, V. Ciocca, S. Dessain, T. Evans
Journal: Journal of Thoracic Oncology (2022)
EP08.01-031 Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response
Authors: F. Lusky, H. Schindler, M. Elshiaty, L. Gaissmaier, L. Daniello, F. Bozorgmehr, J. Kuon, R. Shah, M.A. Schneider, F. Eichhorn, F. Trudzinski, A. Angeles, F. Janke, M. Kirchner, D. Kazdal, A. Stenzinger, H. Sültmann, M. Thomas, P. Christopoulos
Journal: Journal of Thoracic Oncology (2022)
EP07.01-019 Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma
Authors: T. Kutuk, J. Walker, M.T. Ballo, R.B. Cameron, J. Bustamante Alvarez, S. Chawla, E. Luk, D. Behl, A. Dal Pra, N. Morganstein, T. Refaat, A. Sheybani, C. Squillante, J. Zhang, R. Kotecha
Journal: Journal of Thoracic Oncology (2022)
EP16.04-025 Statins Suppress SOAT1 Expression &amp; Reduce Cholesterol Esterification in Statin-sensitive Lung Cancer Cells
Authors: K. Warita, A. Sugiura, J. Tashiro, Y. Hosaka, N. Irie, Y. Zhou, T. Warita, Z.N. Oltvai
Journal: Journal of Thoracic Oncology (2022)
EP08.02-011 Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
Authors: A. Aguilar, M. Cobo, A. Azkárate, A. Calles, M.Á. Molina, R. Rosell
Journal: Journal of Thoracic Oncology (2022)
EP07.03-006 Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data
Authors: T. Kutuk, H. Appel, M.C. Avedano, F. Albrecht, P. Kaywin, S. Ramos, M. Suarez-Murias, M.P. Mehta, R. Kotecha
Journal: Journal of Thoracic Oncology (2022)
EP10.01-015 The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Authors: A.M. Morelli, I. Capizzi, M. Bungaro, F. Solitro, L. Eletti, S. Martinetto, A. Veltri, M. Tinivella, P. Pedrazzoli, R. Caccialanza, V. Bertaglia, E. Capelletto, M.L. Reale, M. Tampellini, S. Novello
Journal: Journal of Thoracic Oncology (2022)